A Systematic Review of the Efficacy and Toxicity of Brachytherapy Boost Combined with External Beam Radiotherapy for Nonmetastatic Prostate Cancer
Tóm tắt
Từ khóa
Tài liệu tham khảo
European Association of Urology. Prostate cancer. 2022. https://uroweb.org/guideline/prostate-cancer/.
Henry, 2022, GEC-ESTRO ACROP prostate brachytherapy guidelines, Radiother Oncol, 167, 244, 10.1016/j.radonc.2021.12.047
AUA/ASTRO/SUO. AUA/ASTRO/SUO guideline on clinically localized prostate cancer. 2017. https://www.astro.org/Patient-Care-and-Research/Clinical-Practice-Statements/ASTRO-39;s-evidence-based-guideline-on-clinically.
National Comprehensive Cancer Network. Prostate cancer (version 4.2022). 2022. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1459.
Higgins JPT, Thomas J, Chandler J, et al. Cochrane handbook for systematic reviews of interventions version 6.3 (updated February 2022). 2022. www.training.cochrane.org/handbook.
Page, 2021, The PRISMA 2020 statement: an updated guideline for reporting systematic reviews, BMJ, 372
Hoskin, 2021, Randomised trial of external-beam radiotherapy alone or with high-dose-rate brachytherapy for prostate cancer: mature 12-year results, Radiother Oncol, 154, 214, 10.1016/j.radonc.2020.09.047
Parmar, 1998, Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints, Stat Med, 17, 2815, 10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8
Aas, 2021, Comparative survival outcomes of high-risk prostate cancer treated with radical prostatectomy or definitive radiotherapy regimens, Eur Urol Open Sci, 26, 55, 10.1016/j.euros.2021.01.011
Abugharib, 2017, External beam radiation therapy with or without low-dose-rate brachytherapy: analysis of favorable and unfavorable intermediate-risk prostate cancer patients, Brachytherapy, 16, 782, 10.1016/j.brachy.2017.04.001
Amini, 2016, Survival outcomes of dose-escalated external beam radiotherapy versus combined brachytherapy for intermediate and high risk prostate cancer using the national cancer data base, J Urol, 195, 1453, 10.1016/j.juro.2015.11.005
Andruska, 2022, Assessing the impact of brachytherapy boost and androgen deprivation therapy on survival outcomes for patients with unfavorable intermediate-risk prostate cancer patients treated with external beam radiotherapy, Brachytherapy, 21, 617, 10.1016/j.brachy.2022.04.001
Chen, 2020, Survival outcomes of radical prostatectomy + extended pelvic lymph node dissection and radiotherapy in prostate cancer patients with a risk of lymph node invasion over 5%: a population-based analysis, Front Oncol, 10, 10.3389/fonc.2020.607576
Chen, 2021, Stereotactic body radiation therapy and high-dose-rate brachytherapy boost in combination with intensity modulated radiation therapy for localized prostate cancer: a single-institution propensity score matched analysis, Int J Radiat Oncol Biol Phys, 110, 429, 10.1016/j.ijrobp.2020.12.034
David, 2021, Outcomes with brachytherapy based dose escalation for Gleason 8 versus 9–10 prostate cancer: an NCDB analysis, Urol Oncol, 39, 829.e19, 10.1016/j.urolonc.2021.04.014
Elliott Sean, 2007, Incidence of urethral stricture after primary treatment for prostate cancer: data from CaPSURE, J Urol, 178, 529, 10.1016/j.juro.2007.03.126
Ennis, 2018, Brachytherapy-based radiotherapy and radical prostatectomy are associated with similar survival in high-risk localized prostate cancer, J Clin Oncol, 36, 1192, 10.1200/JCO.2017.75.9134
Fletcher, 2006, Case-matched comparison of contemporary radiation therapy to surgery in patients with locally advanced prostate cancer, Int J Radiat Oncol Biol Phys, 66, 1092, 10.1016/j.ijrobp.2006.06.019
Foster, 2019, Application of a prognostic stratification system for high-risk prostate cancer to patients treated with radiotherapy: implications for treatment optimization, Am J Clin Oncol, 42, 382, 10.1097/COC.0000000000000521
Freiberger, 2017, Long-term prognostic significance of rising PSA levels following radiotherapy for localized prostate cancer—focus on overall survival, Radiat Oncol, 12, 98, 10.1186/s13014-017-0837-5
Glaser, 2017, Brachytherapy boost for prostate cancer: trends in care and survival outcomes, Brachytherapy, 16, 330, 10.1016/j.brachy.2016.12.015
Guo, 2021, Comparison of oncological outcomes between radical prostatectomy and radiotherapy by type of radiotherapy in elderly prostate cancer patients, Front Oncol, 11, 10.3389/fonc.2021.797462
Helou, 2014, A comparative study of quality of life in patients with localized prostate cancer treated at a single institution: stereotactic ablative radiotherapy or external beam+high dose rate brachytherapy boost, Radiother Oncol, 113, 404, 10.1016/j.radonc.2014.10.013
Huang, 2019, Evaluation of cancer specific mortality with surgery versus radiation as primary therapy for localized high grade prostate cancer in men younger than 60 years, J Urol, 201, 120, 10.1016/j.juro.2018.07.049
Jackson, 2017, Prostate brachytherapy, either alone or in combination with external beam radiation, is associated with longer overall survival in men with favorable pathologic group 4 (Gleason score 8) prostate cancer, Brachytherapy, 16, 790, 10.1016/j.brachy.2017.03.007
Jarosek, 2015, Propensity-weighted long-term risk of urinary adverse events after prostate cancer surgery, radiation, or both, Eur Urol, 67, 273, 10.1016/j.eururo.2014.08.061
Jayadevappa, 2019, Comparative effectiveness of treatments for high-risk prostate cancer patients, Urol Oncol, 37, 574.e11, 10.1016/j.urolonc.2019.06.005
Jiang, 2015, The burden of overtreatment: comparison of toxicity between single and combined modality radiation therapy among low risk prostate cancer patients, Can J Urol, 22, 7648
Jo, 2005, Radical prostatectomy versus high-dose rate brachytherapy for prostate cancer: effects on health-related quality of life, BJU Int, 96, 43, 10.1111/j.1464-410X.2005.05564.x
Joseph, 2020, Radiation dose escalation or longer androgen suppression to prevent distant progression in men with locally advanced prostate cancer: 10-year data from the TROG 03.04 RADAR trial, Int J Radiat Oncol Biol Phys, 106, 693, 10.1016/j.ijrobp.2019.11.415
Kent, 2019, Improved survival for patients with prostate cancer receiving high-dose-rate brachytherapy boost to EBRT compared with EBRT alone, Brachytherapy, 18, 313, 10.1016/j.brachy.2019.01.013
Kestin, 2000, Matched-pair analysis of conformal high–dose-rate brachytherapy boost versus external-beam radiation therapy alone for locally advanced prostate cancer, J Clin Oncol, 18, 2869, 10.1200/JCO.2000.18.15.2869
Khor, 2013, Direct 2-arm comparison shows benefit of high-dose-rate brachytherapy boost vs external beam radiation therapy alone for prostate cancer, Int J Radiat Oncol Biol Phys, 85, 679, 10.1016/j.ijrobp.2012.07.006
King, 2019, A comparative analysis of overall survival between high-dose-rate and low-dose-rate brachytherapy boosts for unfavorable-risk prostate cancer, Brachytherapy, 18, 186, 10.1016/j.brachy.2018.12.007
Kishan, 2018, Radical prostatectomy, external beam radiotherapy, or external beam radiotherapy with brachytherapy boost and disease progression and mortality in patients with Gleason score 9–10 prostate cancer, JAMA, 319, 896, 10.1001/jama.2018.0587
Kishan, 2021, Comparison of multimodal therapies and outcomes among patients with high-risk prostate cancer with adverse clinicopathologic features, JAMA Network Open, 4, e2115312, 10.1001/jamanetworkopen.2021.15312
Kishan, 2017, Clinical outcomes for patients with Gleason score 9–10 prostate adenocarcinoma treated with radiotherapy or radical prostatectomy: a multi-institutional comparative analysis, Eur Urol, 71, 766, 10.1016/j.eururo.2016.06.046
Kupelian, 2004, Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy ≥72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1–T2 prostate cancer, Int J Radiat Oncol Biol Phys, 58, 25, 10.1016/S0360-3016(03)00784-3
Lee, 2018, Comparison of patient-reported outcomes after external beam radiation therapy and combined external beam with low-dose-rate brachytherapy boost in men with localized prostate cancer, Int J Radiat Oncol Biol Phys, 102, 116, 10.1016/j.ijrobp.2018.05.043
Liss, 2015, Combination therapy improves prostate cancer survival for patients with potentially lethal prostate cancer: the impact of Gleason pattern 5, Brachytherapy, 14, 502, 10.1016/j.brachy.2015.02.389
Luo, 2018, Long-term oncologic outcomes of radiotherapy combined with maximal androgen blockade for localized, high-risk prostate cancer, World J Surg Oncol, 16, 107, 10.1186/s12957-018-1395-5
Muralidhar, 2016, Brachytherapy boost and cancer-specific mortality in favorable high-risk versus other high-risk prostate cancer, J Contemp Brachyther, 8, 1, 10.5114/jcb.2016.58080
Nemirovsky, 2021, Surgery associated with increased survival compared to radiation in clinically localized Gleason 9–10 prostate cancer: a SEER analysis, World J Urol, 39, 415, 10.1007/s00345-020-03215-x
Oshikane, 2021, A comparative study of high-dose-rate brachytherapy boost combined with external beam radiation therapy versus external beam radiation therapy alone for high-risk prostate cancer, J Radiat Res, 62, 525, 10.1093/jrr/rrab006
Parry, 2021, Impact of high-dose-rate and low-dose-rate brachytherapy boost on toxicity, functional and cancer outcomes in patients receiving external beam radiation therapy for prostate cancer: a national population-based study, Int J Radiat Oncol Biol Phys, 109, 1219, 10.1016/j.ijrobp.2020.11.023
Pasalic, 2021, Five-year outcomes from a prospective comparative effectiveness study evaluating external-beam radiotherapy with or without low-dose-rate brachytherapy boost for localized prostate cancer, Cancer, 127, 1912, 10.1002/cncr.33388
Philipson, 2021, Patterns of clinical progression in radiorecurrent high-risk prostate cancer, Eur Urol, 80, 142, 10.1016/j.eururo.2021.04.035
Savdie, 2012, High-dose rate brachytherapy compared with open radical prostatectomy for the treatment of high-risk prostate cancer: 10 year biochemical freedom from relapse, BJU Int, 110, 71, 10.1111/j.1464-410X.2012.11480.x
Sebastian, 2019, Survival after radiotherapy vs. radical prostatectomy for unfavorable intermediate-risk prostate cancer, Urol Oncol, 37, 813.e11, 10.1016/j.urolonc.2019.04.022
Shen, 2012, The impact of brachytherapy on prostate cancer–specific mortality for definitive radiation therapy of high-grade prostate cancer: a population-based analysis, Int J Radiat Oncol Biol Phys, 83, 1154, 10.1016/j.ijrobp.2011.09.055
Shilkrut, 2016, Treatment outcomes in very high-risk prostate cancer treated by dose-escalated and combined-modality radiation therapy, Am J Clin Oncol, 39, 181, 10.1097/COC.0000000000000043
Shilkrut, 2013, The addition of low-dose-rate brachytherapy and androgen-deprivation therapy decreases biochemical failure and prostate cancer death compared with dose-escalated external-beam radiation therapy for high-risk prostate cancer, Cancer, 119, 681, 10.1002/cncr.27784
Singh, 2005, Combined external beam radiotherapy and Pd-103 brachytherapy boost improves biochemical failure free survival in patients with clinically localized prostate cancer: results of a matched pair analysis, Prostate, 62, 54, 10.1002/pros.20118
Smith, 2015, Brachytherapy improves biochemical failure–free survival in low- and intermediate-risk prostate cancer compared with conventionally fractionated external beam radiation therapy: a propensity score matched analysis, Int J Radiat Oncol Biol Phys, 91, 505, 10.1016/j.ijrobp.2014.11.018
Smolska-Ciszewska, 2015, The effectiveness and side effects of conformal external beam radiotherapy combined with high-dose-rate brachytherapy boost compared to conformal external beam radiotherapy alone in patients with prostate cancer, Radiat Oncol, 10, 60, 10.1186/s13014-015-0366-z
Song, 2022, The prognosis of radical prostatectomy, external beam radiotherapy plus brachytherapy, and external beam radiotherapy alone for patients above 70 years with very high-risk prostate cancer: a population-matched study, Urol Int, 106, 11, 10.1159/000518113
Tamihardja, 2022, Propensity score-matched analysis comparing dose-escalated intensity-modulated radiation therapy versus external beam radiation therapy plus high-dose-rate brachytherapy for localized prostate cancer, Strahlenther Onkol, 198, 735, 10.1007/s00066-022-01953-y
Tilki, 2019, Surgery vs radiotherapy in the management of biopsy Gleason score 9–10 prostate cancer and the risk of mortality, JAMA Oncol, 5, 213, 10.1001/jamaoncol.2018.4836
Tunio, 2012, Conformal radiotherapy plus high dose rate brachytherapy prostate boost in patients with intermediate and high risk prostate cancer: our experience in Asian males, J Radiother Pract, 11, 257, 10.1017/S1460396912000234
Tward, 2020, Metastasis, mortality, and quality of life for men with NCCN high and very high risk localized prostate cancer after surgical and/or combined modality radiotherapy, Clin Genitourin Cancer, 18, 274, 10.1016/j.clgc.2019.11.023
Wang, 2017, Racial disparity in prostate cancer-specific mortality for high-risk prostate cancer: a population-based study, Cureus, 9, e961
Wedde, 2019, Ten-year survival after high-dose-rate brachytherapy combined with external beam radiation therapy in high-risk prostate cancer: a comparison with the Norwegian SPCG-7 cohort, Radiother Oncol, 132, 211, 10.1016/j.radonc.2018.10.013
Wenzel, 2022, The impact of time to prostate specific antigen nadir on biochemical recurrence and mortality rates after radiation therapy for localized prostate cancer, Urol Oncol, 40, 57.e15, 10.1016/j.urolonc.2021.06.025
Xiang, 2015, Significant association of brachytherapy boost with reduced prostate cancer–specific mortality in contemporary patients with localized, unfavorable-risk prostate cancer, Brachytherapy, 14, 773, 10.1016/j.brachy.2015.09.004
Yamazaki, 2022, Comparison of toxicities between ultrahypofractionated radiotherapy versus brachytherapy with or without external beam radiotherapy for clinically localized prostate cancer, Sci Rep, 12, 5055, 10.1038/s41598-022-09120-0
Yamazaki, 2022, Conventional dose versus dose escalated radiotherapy including high-dose-rate brachytherapy boost for patients with Gleason score 9–10 clinical localized prostate cancer, Sci Rep, 12, 268, 10.1038/s41598-021-04233-4
Yamazaki, 2021, Novel prognostic index of high-risk prostate cancer using simple summation of very high-risk factors, Cancers, 13, 3486, 10.3390/cancers13143486
Yamazaki, 2021, Radiotherapy for clinically localized T3b or T4 very-high-risk prostate cancer-role of dose escalation using high-dose-rate brachytherapy boost or high dose intensity modulated radiotherapy, Cancers, 13, 1856, 10.3390/cancers13081856
Yang, 2018, Lack of apparent survival benefit with use of androgen deprivation therapy in patients with high-risk prostate cancer receiving combined external beam radiation therapy and brachytherapy, Int J Radiat Oncol Biol Phys, 100, 53, 10.1016/j.ijrobp.2017.08.046
Yin, 2020, Comparative effectiveness of surgery versus external beam radiation with/without brachytherapy in high-risk localized prostate cancer, Cancer Med, 9, 27, 10.1002/cam4.2605
De, 2022, Patient-reported outcomes after external beam radiotherapy with low dose rate brachytherapy boost vs radical prostatectomy for localized prostate cancer: five-year results from a prospective comparative effectiveness study, J Urol, 208, 1226, 10.1097/JU.0000000000002902
Krauss, 2023, Dose-escalated radiotherapy alone or in combination with short-term androgen deprivation for intermediate-risk prostate cancer: results of a phase III multi-institutional trial, J Clin Oncol, 41, 3203, 10.1200/JCO.22.02390
Yamazaki, 2022, Role of brachytherapy boost in clinically localized intermediate and high-risk prostate cancer: lack of benefit in patients with very high-risk factors T3b–4 and/or Gleason 9–10, Cancers, 14, 2976, 10.3390/cancers14122976
Agrawal, 2022, Pattern of radiotherapy treatment in low-risk, intermediate-risk, and high-risk prostate cancer patients: analysis of National Cancer Database, Cancers, 14, 5503, 10.3390/cancers14225503
Miszczyk, 2023, Brachytherapy boost improves survival and decreases risk of developing distant metastases compared to external beam radiotherapy alone in intermediate and high risk group prostate cancer patients, Radiother Oncol, 183, 10.1016/j.radonc.2023.109632
Patel, 2022, External beam radiotherapy with or without brachytherapy boost in men with very high-risk prostate cancer: a large multicenter international consortium analysis, Int J Radiat Oncol Biol Phys, 115, 645, 10.1016/j.ijrobp.2022.09.075
Patel, 2023, Association of brachytherapy boost with overall survival for Gleason 9–10 prostate cancer: the impact of primary versus secondary pattern 5, Brachytherapy, 22, 310, 10.1016/j.brachy.2022.12.004
Kishan, 2022, Interplay between duration of androgen deprivation therapy and external beam radiotherapy with or without a brachytherapy boost for optimal treatment of high-risk prostate cancer: a patient-level data analysis of 3 cohorts, JAMA Oncol, 8, e216871, 10.1001/jamaoncol.2021.6871
Tsumura, 2022, Direct comparison of low-dose-rate brachytherapy versus radical prostatectomy using the surgical definition of biochemical recurrence for patients with intermediate-risk prostate cancer, Radiat Oncol, 17, 71, 10.1186/s13014-022-02046-x
Xie, 2017, Metastasis-free survival is a strong surrogate of overall survival in localized prostate cancer, J Clin Oncol, 35, 3097, 10.1200/JCO.2017.73.9987
Roy, 2023, Biochemical recurrence surrogacy for clinical outcomes after radiotherapy for adenocarcinoma of the prostate, J Clin Oncol, 41, 5005, 10.1200/JCO.23.00617
Lawton, 2011, Long-term results of a phase II trial of ultrasound-guided radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate (RTOG 98–05), Int J Radiat Oncol Biol Phys, 81, 1, 10.1016/j.ijrobp.2010.05.056
Zelefsky, 2007, Multi-institutional analysis of long-term outcome for stages T1–T2 prostate cancer treated with permanent seed implantation, Int J Radiat Oncol Biol Phys, 67, 327, 10.1016/j.ijrobp.2006.08.056
Kishan, 2020, Local failure and survival after definitive radiotherapy for aggressive prostate cancer: an individual patient-level meta-analysis of six randomized trials, Eur Urol, 77, 201, 10.1016/j.eururo.2019.10.008
Kerkmeijer, 2021, Focal boost to the intraprostatic tumor in external beam radiotherapy for patients with localized prostate cancer: results from the FLAME randomized phase III trial, J Clin Oncol, 39, 787, 10.1200/JCO.20.02873
Draulans, 2020, Primary endpoint analysis of the multicentre phase II hypo-FLAME trial for intermediate and high risk prostate cancer, Radiother Oncol, 147, 92, 10.1016/j.radonc.2020.03.015
Rodda, 2017, An Analysis of Treatment-Related Morbidity for A Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to A Dose-Escalated External Beam Boost for High- and Intermediate-Risk Prostate Cancer, Int J Radiat Oncol Biol Phys, 98, 286, 10.1016/j.ijrobp.2017.01.008
2017, An Analysis of Health-Related Quality of Life for a Randomized Trial Comparing Low-Dose-Rate Brachytherapy Boost With Dose-Escalated External Beam Boost for High- and Intermediate-Risk Prostate Cancer, Int J Radiat Oncol Biol Phys, 98, 581, 10.1016/j.ijrobp.2017.02.027